Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...

At the Haematocon 2024 conference in Nagpur, India, Hemex Health announced new product offerings for the Company’s Gazelle™ ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The SOMERVILLE, Mass., November 05, 2024--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition We ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

Newborn screening is a fundamental right for every child, crucial for early diagnosis and intervention of preventable ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Last year, it got the nod for Casgevy, a gene-editing treatment for two rare blood disorders: transfusion-dependent beta-thalassemia and sickle cell disease. Gene-editing therapies are complex to ...

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ...

More recently, Bluebird Bio’s Zynteglo (betibeglogene autotemcel), a cell-based gene therapy to treat transfusion-dependent beta-thalassemia (TDT), has been slow to gain traction in the market.